Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah

 
• By Leela Barham

Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.

Meeting
Early engagement has helped Novartis overcome payer reservations • Source: Shutterstock

More from Pricing Debate

More from Market Access